252 related articles for article (PubMed ID: 16261868)
1. [Response rates following neoadjuvant chemotherapy and breast preserving treatment in patients with locally advanced breast cancer].
Maráz R; Boross G; Svébis M; Gyánti R; Vizhányó R; Hajnal L; Markó L; Szucs M; Ambrózay E; Lorincz M
Magy Seb; 2005 Aug; 58(4):225-32. PubMed ID: 16261868
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
3. Treatment options for locally advanced breast cancer--experience in an Asian tertiary hospital.
Chong HY; Taib NA; Rampal S; Saad M; Bustam AZ; Yip CH
Asian Pac J Cancer Prev; 2010; 11(4):913-7. PubMed ID: 21133600
[TBL] [Abstract][Full Text] [Related]
4. [Primary systemic therapy in breast cancer patients (2007-2010)].
Zapf I; Tizedes G; Pavlovics G; Kovács G; Kálmán E; Szalai G; Kövér E; Farkas R; Horváth OP
Magy Seb; 2011 Oct; 64(5):223-8. PubMed ID: 21997525
[TBL] [Abstract][Full Text] [Related]
5. Retrospective study of efficacy and safety of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive locally advanced and oligometastatic breast cancer: An Indian experience.
Tiwari A; Gogia A; Deo S; Shukla NK; Mathur S; Sharma DN
Indian J Cancer; 2017; 54(1):343-346. PubMed ID: 29199719
[TBL] [Abstract][Full Text] [Related]
6. High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin.
Chen SC; Chang HK; Lin YC; Hsueh S; Cheung YC; Leung WM; Tsai CS; Lo YF; Tsai HP; Shen SC; Chen MF
Jpn J Clin Oncol; 2008 Feb; 38(2):99-105. PubMed ID: 18270380
[TBL] [Abstract][Full Text] [Related]
7. Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancer patients in Northeast China.
Lv M; Li B; Li Y; Mao X; Yao F; Jin F
Asian Pac J Cancer Prev; 2011; 12(9):2411-7. PubMed ID: 22296393
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy for local advanced breast cancer with stage IIIB.
Kim R; Osaki A; Tanabe K; Toge T
Oncol Rep; 2004 Jun; 11(6):1265-72. PubMed ID: 15138565
[TBL] [Abstract][Full Text] [Related]
9. [Clinical evaluation of effects from neoadjuvant chemotherapy with epirubicin plus paclitaxel in cases of locally advanced breast cancer--comparative study of treatment with 2 and 4 cycles].
Tong F; Yang D; Zhou B; Cao Y; Liu P; Liu H; Wang S; Qiao X; Zhang J
Gan To Kagaku Ryoho; 2004 Feb; 31(2):205-8. PubMed ID: 14997752
[TBL] [Abstract][Full Text] [Related]
10. [Axillary pathologic response after neoadjuvant chemotherapy in locally advanced breast cancer with axillary involvement].
Jiménez-Ballvé A; Serrano-Palacio A; García-Sáenz JA; Ortega Candil A; Salsidua-Arroyo O; Román-Santamaría JM; Pelayo Alarcón A; Fuentes Ferrer ME; Carreras-Delgado JL
Rev Esp Med Nucl Imagen Mol; 2015; 34(4):230-5. PubMed ID: 25743035
[TBL] [Abstract][Full Text] [Related]
11. [Assessment of neoadjuvant chemotherapy in breast cancer patients].
Zhang B; Zhang Q; Zhao L; Long F; Li S; Jiang DQ; Xu H
Zhonghua Zhong Liu Za Zhi; 2006 Nov; 28(11):867-70. PubMed ID: 17416014
[TBL] [Abstract][Full Text] [Related]
12. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression.
Ando M; Yamauchi H; Aogi K; Shimizu S; Iwata H; Masuda N; Yamamoto N; Inoue K; Ohono S; Kuroi K; Hamano T; Sukigara T; Fujiwara Y
Breast Cancer Res Treat; 2014 Jun; 145(2):401-9. PubMed ID: 24728578
[TBL] [Abstract][Full Text] [Related]
14. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
[TBL] [Abstract][Full Text] [Related]
15. Oncologic safety of breast-conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer.
Cho JH; Park JM; Park HS; Park S; Kim SI; Park BW
J Surg Oncol; 2013 Dec; 108(8):531-6. PubMed ID: 24115142
[TBL] [Abstract][Full Text] [Related]
16. [Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer. Its relation with molecular subtypes].
Ruano R; Ramos M; García-Talavera JR; Ramos T; Rosero AS; González-Orus JM; Sancho M
Rev Esp Med Nucl Imagen Mol; 2014; 33(6):340-5. PubMed ID: 24856234
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in operable breast cancer treated with neoadjuvant chemotherapy: towards a quantification of residual disease.
Mombelli S; Kwiatkowski F; Abrial C; Wang-Lopez Q; de Boissieu P; Garbar C; Bensussan A; Curé H
Oncology; 2015; 88(5):261-72. PubMed ID: 25573741
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy with taxotere-epirubicin-5-fluorouracil (TEF) in local-regionally advanced breast cancer: a preliminary report.
Baltali E; Altundağ MK; Onat DA; Abbasoğlu O; Ozişik Y; Güler N; Atahan L; Berberoğlu U; Altinok M; Baran I; Celik I; Tekuzman G
Tumori; 2002; 88(6):474-7. PubMed ID: 12597141
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
Untch M; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; von Minckwitz G
J Clin Oncol; 2010 Apr; 28(12):2024-31. PubMed ID: 20308670
[TBL] [Abstract][Full Text] [Related]
20. [Neoadjuvant treatment for locally advanced breast cancer. Comparison of two schemes based on docetaxel-epirubicin vs. 5-fluorouracil-epirubicin-cyclophosphamide].
Cortés-Flores AO; Morgan-Villela G; Castro-Cervantes JM; Vázquez-Camacho G; Fuentes-Orozco C; González-Ojeda A
Cir Cir; 2008; 76(1):23-8. PubMed ID: 18492416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]